KBA1413 / Kling Biotherapeutics - LARVOL DELTA

Affinity optimized KBA1413, an antibody derived from a cured AML patient with broad reactivity against AML and other myeloid malignancies, shows efficient internalization. (CICON 2025) - "High affinity variants of KBA1413 (KBA1413-EVO) show a 100x increased affinity and strong internalization in AML cell lines compared to the parental and compared to CD33 targeted antibodies. KBA1413-EVO shows promise as new ADC agent with therapeutic applications for AML and solid tumors where the target is overexpressed."

Clinical • Acute Myelogenous Leukemia • Breast Cancer • Hematological Malignancies • Leukemia • Melanoma • Myelodysplastic Syndrome • Oncology • Solid Tumor • CD33 • SPN

KBA1413: An antibody derived from a cured AML patient, recognizes a unique glycoepitope shared by AML, MDS and several solid cancer cells (ESMO-TAT 2025) - "To increase its therapeutic potential KBA1413 was made into a bispecific T-cell engaging antibody (bTCE) that induced potent cytotoxicity in vitro and in vivo on cell lines and primary AML. Bifunctional targeting of AML with KBA1413 and a CD33 binder induced potent ADCC activitycytotoxicity in vitro, outperforming single agent activity. To increase the affinity of KBA1413, we further optimized binding of KBA1413 with employed the Kling-Evolve platform, this allows for the in vitro maturation of B cell clones against targets of interest."

Clinical • Acute Myelogenous Leukemia • Breast Cancer • Hematological Malignancies • Leukemia • Melanoma • Myelodysplastic Syndrome • Oncology • Solid Tumor • CD33 • SPN

Melanoma cells can be eliminated by sialylated CD43 × CD3 bispecific T cell engager formats in vitro and in vivo. (PubMed, Cancer Immunol Immunother) - "Treatment with both AT1413 bTCE and AT1413 KiH significantly reduced tumor outgrowth in these mice. These data indicate a broad therapeutic potential of AT1413 that includes AML and CD43s-expressing solid tumors that originate from CD43-negative tissues."

Journal • Preclinical • Acute Myelogenous Leukemia • Breast Cancer • Genetic Disorders • Hematological Malignancies • Leukemia • Melanoma • Myelodysplastic Syndrome • Oncology • Skin Cancer • Solid Tumor • Transplantation • SPN

KBA1413, an antibody derived from a cured AML patient, recognizes a unique CD43 glycoform shared by AML, MDS and solid cancer cells (ESMO-TAT 2024) - P1 | "ClinicalTrials.gov: NCT05501821. Conclusions Kling Biotherapeutics has discovered several unique cancer targets and their corresponding human antibodies that are currently in preclinical development such as targeting snRNP200 and a novel, truncated form of E-cadherin. KBA1412, a CD9-targeting human antibody is currently being evaluated in a phase 1b dose escalation and dose expansion study in patients with advanced solid tumors."

Clinical • Acute Myelogenous Leukemia • Breast Cancer • Melanoma • Myelodysplastic Syndrome • Oncology • Solid Tumor • CD9 • CDH1 • SPN

Kling Biotherapeutics to Present Discoveries on its Primary B-Cell Screening Platform at the ESMO Targeted Anticancer Therapies Congress (PRNewswire) - "KBA1413 triggered TR NK-mediated antibody dependent cell-mediated cytotoxicity (ADCC) against AML cells both in vitro and in vivo, suggesting that the antibody played a role in the graft versus leukemia response of the original donor patient. KBA1413 was made into a bispecific T-cell engaging antibody (bTCE), to increase its therapeutic potential and induced potent cytotoxicity in vitro and in vivo on cell lines in primary AML....Data demonstrates that KBA1413 warrants further development as a potent and promising treatment candidate for AML, MDS and solid tumors."

Clinical • Acute Myelogenous Leukemia • Myelodysplastic Syndrome • Solid Tumor